Companies/Bausch + Lomb Corporation

Company profile

Bausch + Lomb Corporation

NYSE: BLCO · Healthcare · Medical - Instruments & Supplies

Canadian filerHQ Vaughan, ONCIK 0001860742Reports USD

#60 of 1,394 Healthcare companies by revenue51st-percentile growth

EA Score

66B

FH 70DQ 60GM 67SS 66

v0.1 · 65/100 weight · provisional

↑ filing timeliness, workforce scale · ↓ listing tenure, disclosure history

Methodology →

Revenue TTM

$5.2B

Rev growth YoY (TTM)

+7.8%

Net income (FY)

-$360.0M

Employees

13,500

Market cap

$6.1B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$5.1B$5.1B2025

Net income-$360.0M-$360.0M2025

Operating income$113.0M$113.0M2025

Total assets$14.0B$14.0B2025

Liabilities$7.5B$7.5B2025

Equity$6.4B$6.4B2025

Revenue trend

FY2022 – FY2025 · USD

$3.4B

FY22

$3.8B

FY22

$3.8B

FY22

$4.1B

FY23

$4.8B

FY24

$5.1B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Device Products38%

Over the Counter Products36%

Pharmaceutical Products21%

Branded and Other Generic Products5%

Other Revenues0%

By geography

United States and Puerto Rico53%

Other Countries16%

CHINA7%

FRANCE5%

JAPAN4%

GERMANY3%

The read

Bausch + Lomb Corporation booked $5.1B in FY2025 revenue, growing 6.5% year over year — about the middle of the pack among Healthcare companies we track, at a -7.1% net margin.

Peers · Healthcare

Twist Bioscience Corporation70B CG Oncology Inc.47D Mirum Pharmaceuticals, Inc.64C Teleflex Incorporated77B+

Key facts

CEOBrenton L. Saunders

SectorHealthcare

IndustryMedical - Instruments & Supplies

HeadquartersVaughan, ON

ExchangeNYSE: BLCO

Employees13,500

IPO date2022-05-06

Latest filings

8-K2026-05-20 8-K2026-04-29 10-Q2026-04-29 DEF 14A2026-04-10 10-K2026-02-18 8-K2026-02-18 8-K2026-01-02 8-K2025-12-17

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.